Safety, Tolerance and Pharmacokinetics Study of Compound Edaravone Injection

NCT04219865 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Pharmacokinetics

Interventions

DRUG: Group 1: Compound Edaravone/Placebo Injection
DRUG: Group 2: Compound Edaravone/Placebo Injection
DRUG: Group 3: Compound Edaravone/Placebo Injection
DRUG: Group 4: Compound Edaravone/Placebo Injection
DRUG: Group 5: Compound Edaravone/Placebo Injection

Sponsor

Nanjing Yoko Biomedical Co., Ltd.